Name: CD96 (Nelistotug Biosimilar) Recombinant Monoclonal Antibody
Brand: CUSABIO
SKU: CSB-RA004971MB2HU

Product Details

Uniprot No.

P40200

Target Names

CD96

Alternative Names

GSK-6097608 research-grade biosimilar ;CD96 antibody; T-cell surface protein tactile antibody; Cell surface antigen CD96 antibody; T cell-activated increased late expression protein antibody; CD antigen CD96 antibody

Species Reactivity

Human

Immunogen

Recombinant Human CD96 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

0.01M PBS，pH7.4

Form

Liquid

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Notes

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.

Lead Time

3-4 weeks

Description

This recombinant monoclonal antibody is a research-grade biosimilar to Nelistotug, designed for research applications targeting CD96, a transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD96 is expressed primarily on natural killer (NK) cells and T cell subsets, where it functions as an immune checkpoint receptor by binding to CD155 (PVR) on target cells. This interaction delivers inhibitory signals that dampen NK cell-mediated cytotoxicity and T cell activation, contributing to immune evasion mechanisms. CD96 has emerged as a significant target in immuno-oncology research, particularly in the context of tumor immunity, as its blockade has shown potential to enhance anti-tumor immune responses in various malignancies.

Nelistotug is a clinical-stage therapeutic antibody developed to block CD96-CD155 interactions, thereby releasing the brake on immune cell function and promoting tumor clearance. This biosimilar provides researchers with a valuable tool for investigating CD96 biology, exploring combination immunotherapy strategies, and studying immune checkpoint regulation in oncology and immunology research settings. It enables mechanistic studies of NK cell and T cell function in cancer models and other disease contexts.

Usage

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Target Background

Function

May be involved in adhesive interactions of activated T and NK cells during the late phase of the immune response. Promotes NK cell-target adhesion by interacting with PVR present on target cells. May function at a time after T and NK cells have penetrated the endothelium using integrins and selectins, when they are actively engaging diseased cells and moving within areas of inflammation.

Gene References into Functions

Lower CD96 expression was also observed in human IL-9(+) compared with IFN-gamma(+) T cells PMID: 29531070
Blocking CD96 or TIGIT with mAbs has been shown to improve tumor control in mice. PMID: 27620276
CD96 and CD123 are expressed in bone marrow cells of patients with myelodysplastic syndromes PMID: 26642704
In the present study we analyzed the expression of four cell surface antigens relevant to human hematopoiesis-CD90, CD96, CD117, and CD123-in bone marrow from pediatric acute myeloid leukemia patients and normal control subjects. PMID: 24751333
down-regulation of CD96 is an important aspect of HIV-1 pathogenesis and differential expression is related to cell effector functions and HIV-1 disease course. PMID: 23272144
CD96 could serve as a target structure for effector cell-mediated lysis. PMID: 22879978
The positive expression of CD96 on bone marrow hematopoietic stem cells in patients with acute leukemia may be associated with primary drug resistance, relapse and progression. PMID: 21729528
CD96 promotes natural killer (NK) cell adhesion to target cells expressing the poliovirus receptor (PVR), stimulates cytotoxicity of activated NK cells, and mediates acquisition of PVR from target cells. PMID: 15034010
CD96 is a cell surface marker present on many acute myeloid leukemia leukemic stem cells PMID: 17576927
CD96-driven adhesion to CD155 may be crucial in developmental processes PMID: 19056733

Hide All

Involvement in disease

C syndrome (CSYN)

Subcellular Location

Membrane; Single-pass type I membrane protein.

Tissue Specificity

Expressed on normal T-cell lines and clones, and some transformed T-cells, but no other cultured cell lines tested. It is expressed at very low levels on activated B-cells.

Database Links

HGNC: 16892

OMIM: 211750

KEGG: hsa:10225

STRING: 9606.ENSP00000283285

UniGene: Hs.142023

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA004971MB2HU
Size	US$9799
	Order now
Have Questions?	Leave a Message or Start an on-line Chat

CD96 (Nelistotug Biosimilar) Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background